Zostavax Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The zostavax market research report is one of a series of new reports that provides zostavax market statistics, including zostavax industry global market size, regional shares, competitors with a zostavax market share, detailed zostavax market segments, market trends and opportunities, and any further data you may need to thrive in the zostavax industry. This zostavax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to a surge in new shingles vaccine approvals by regulatory authorities, increasing cost-effectiveness of vaccines over treatments, a rise in new vaccine approvals, high adoption of shingrix among the developed countries, and increasing prevalence of chronic diseases. Major trends in the forecast period include a shift toward advanced products, emerging initiatives from companies in research and development of vaccines, government initiatives and public health campaigns, expanding outreach programs in rural areas to increase awareness and accessibility of the shingles vaccine, and technological advancement.

The growth of the Zostavax market is expected to benefit from the expansion of healthcare infrastructure in developing countries. Healthcare infrastructure encompasses the network of facilities, equipment, personnel, and systems necessary for delivering effective healthcare services. The expansion of these systems is largely driven by increased investments in healthcare facilities and better access to medical services. This infrastructure is crucial for the distribution of Zostavax, as it ensures that clinics, hospitals, and pharmacies are equipped to provide the vaccine to the appropriate population. For example, in May 2023, the UK government allocated more than $25 billion to its New Hospital Programme, aimed at building 40 new hospitals by 2030. This includes efforts to enhance mental health care and overall health service equality. Such investments in healthcare infrastructure in developing countries are likely to boost the Zostavax market.

The growing geriatric population is another factor contributing to the expansion of the Zostavax market. The geriatric population, typically individuals aged 65 and older, often faces age-related health issues and requires specialized care. The global increase in this demographic is primarily due to advances in healthcare, better living standards, and improved disease management, all of which contribute to longer life expectancies. Aging leads to a weakened immune system, which heightens the risk of developing shingles and its complications, making vaccines such as Zostavax crucial for prevention. For instance, the World Health Organization reported that by 2030, one in six people worldwide will be over 60, with this number expected to rise from 1 billion in 2020 to 1.4 billion. The population of those aged 80 or older is projected to triple between 2020 and 2050, further driving the demand for vaccines in this demographic.

Increased insurance coverage is expected to further stimulate the growth of the Zostavax market. As awareness of health risks increases, along with rising medical costs, more people are seeking financial protection against unforeseen health issues. This trend has led to a rise in insurance coverage, which makes vaccines such as Zostavax more accessible. Insurance policies often cover preventive measures such as vaccines, which help to reduce the risk of more expensive treatments for conditions such as shingles. For example, in December 2023, the U.S. Centers for Medicare & Medicaid Services reported that insurance coverage reached a historic high of 92% in 2022, with significant increases in both Medicaid and private insurance enrollments. This rising insurance coverage is helping to make vaccines more widely available and adopted.

The key company operating in the zostavax market is Merck & Co. Inc.

North America was the largest region in the zostavax market in 2024. The regions covered in zostavax report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zostavax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Zostavax is a vaccine developed to prevent shingles, a painful rash caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. It is primarily recommended for adults aged 50 and older to reduce the risk of developing shingles and its associated complications, such as postherpetic neuralgia.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations of Zostavax include the recombinant vaccine (Shingrix) and the live attenuated vaccine (Zostavax). A recombinant vaccine is produced using genetic engineering to create an antigen that triggers an immune response without using a live virus. Zostavax is used for shingles prevention and to reduce the risk of post-herpetic neuralgia, and it is distributed through hospitals and retail pharmacies.

The zostavax market consists of sales of flu vaccines, pneumococcal vaccines hepatitis vaccines and meningitis vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.